Seegene, Becton Dickinson Collaborate to Develop MDx Assays | GenomeWeb

NEW YORK (GenomeWeb) – Becton Dickinson's BD Life Sciences division and Seegene will co-develop multiplex real-time PCR reagents for the BD Max system, the firms announced today.

The deal gives BD worldwide commercialization rights to multiplex tests developed by Seegene for BD's molecular diagnostics platform. The tests will be based on Seegene's core enabling multiplex PCR methods and chemistries: dual-priming oligonucleotide (DPO), tagging oligonucleotide capture and extension (TOCE), and MuDT assay reagents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.